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Abstract
Aim: microRNAs (miRNAs) are involved in various neoplastic diseases, including prostate cancer (PCs). The aim of this study
was to investigate the miRNA profile in PC tissue, to assess their association with clinicopathologic data, and to evaluate the
potential of miRNAs as diagnostic and prognostic markers.
Materials and Methods: From a cohort of 535 patients submitted to radical prostatectomy (RP), a sample of 30 patients (14
patients with rapid biochemical failure (BF) and 16 patients without BF) with Gleason score 7 were analyzed. A total of
1435 miRNAs were quantified by microarray hybridization, and selected miRNAs with the highest Standard deviation
(n = 50) were validated by real-time quantitative PCR (qRT-PCR). In situ hybridization (ISH) was used to evaluate the
expression of miR-21.
Results: miR-21 was the only miR that was significantly up-regulated in the BF group (p = 0.045) miR-21 was up-regulated in
patients with BF compared with non-BF group (p = 0.05). In univariate analyses, high stromal expression of miR-21 had
predictive impact on biochemical failure-free survival (BFFS) and clinical failure-free survival (CFFS) (p = 0.006 and p = 0.04,
respectively). In the multivariate analysis, high stromal expression of miR-21 expression was found to be an independent
prognostic factor for BFFS in patients with Gleason score 6 (HR 2.41, CI 95% 1.06–5.49, p = 0.037).
Conclusion: High stromal expression of miR-21 was associated with poor biochemical recurrence-free survival after RP. For
patients with Gleason score 6, miR-21 may help predict the risk of future disease progression and thereby help select
patients for potential adjuvant treatment or a more stringent follow-up.
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Introduction
Prostate cancer (PC) is the second leading cause of cancer-
related death among males [1]. The disease outcome is variable
and difficult to predict. During the last 30 years, the number of
radical prostatectomies (RP) has increased 25-fold, mainly due to
patients overdiagnosed with nonlethal cancer [2]. Testing for
prostate-specific antigen (PSA) is the most common tool to detect
prostate cancer. However, recent studies have shown that PSA
concentrations are unable to differentiate between indolent and
life-threatening cancers at the time of diagnosis [3]. An
identification of better prognostic markers for risk stratification
will therefore have major impact on the clinical management of
PC.
miRNAs constitute a class of small non-coding RNA molecules
(,20 nucleotides) that are involved in regulating protein
expression. miRNAs can be produced as a by-product from
mRNA production as inter-intron passengers, or can be
transcribed as a single- or polycistronic product by RNA
polymerase II [4]. They work by binding to the 39 UTR of the
target mRNA, and induce silencing of the mRNA by the Argonaut
(Ago) protein in the RNA-induced Silencing protein complex
(RISC) [4,5]. Many miRNAs are deregulated in cancer and
influence on tumor formation and progression because they are
located in regions of the genome that are commonly overexpressed
or deleted [6]. Several miRNAs and their targets are expressed
abnormally in PC, leading to tumor progression, invasion, and
metastasis. The altered expressions of some selected miRNAs are
potentially useful as biomarkers for diagnosis, prognosis, and
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classification purposes of PC [7–9]. miR-21 was the first oncogenic
miRNA to be discovered [10]. In PC, miR-21 is considered to act
as an oncogene, but its role is unclear, and the reports are
conflicting. Hulf et al. [11] found miR-21 to act as a tumor
suppressor gene, while Ribas et al. [12] reported that overexpres-
sion of miR-21 promoted both hormone-dependent and hormone-
independent tumor growth in PC cell lines. Moreover, they
concluded that elevated levels of miR-21 increases tumor
development, tumor growth and induced castration-resistant
phenotype [13]. In contrast, Folini et al. [14] did not find any
differences in miR-21 expression between normal prostate tissue
and PC. Shi et al. [15] found miR-21 to be involved in
chemoresistance and that miR-21 was up-regulated in Docetaxel
resistant PC3 (PCR3) cells compared to wild type PC3 cells.
In this study, we investigated the miRNA profile in PC patients.
Among 1435 miRNAs, miR-21 was the only candidate miRNA
that was significantly up-regulated and underwent further
evaluation as a prognostic marker for the entire cohort. The
Regional Committee for Medical and Health Research Ethics
(2009/1393), the Data Protection Official for Research (NSD),
and the National Data Inspection Board have approved this study.
The ethics committee waived the need for consent. The patient
records was anonymized and de-identified prior to analysis.
Patients and Methods
Patients and tissue samples
Primary tumor tissue from 535 radical prostatectomy (RP)
patients diagnosed at the University Hospital of Northern Norway,
St. Olav Hospital and Nordland Hospital from 1995–2005 were
used in this study. Adequate paraffin embedded tissue blocks and
complete demographic and clinicopathological data were obtained
for all patients (Table 1). The tumors were graded according to the
modified Gleason grading system [16] and staged according to the
WHO guidelines [17]. All primary tissues were histologically
reviewed by two pathologists (ER and LTB).
miRNA screening
For miRNA profiling, 30 patients within the Gleason Score (GS)
7 subgroup were consecutively chosen, 14 of them with a rapid
biochemical failure BF (PSA$0.4 ng/mL within 24 months post-
surgery) and 16 patients with no BF. GS 7 was chosen as these
patients show a heterogenic clinical outcome. The miRNAs were
identified by microarray hybridization and quantified with RT-
qPCR (Table 2). A total of 1435 miRNAs were quantified by
microarray hybridization and selected miRNAs with the highest
standard deviation (n = 50) were validated by quantitative real-
time PCR (qRT-PCR). Seven miRNAs were identified as the most
up- or down-regulated. Of these, miR-21 was the only candidate
miR that was significantly up-regulated by fold-change. MiR-21
expression was then investigated in the entire cohort by
chromogen in situ hybridization (cISH) and evaluated as a
prognostic marker for PC. Both tumor epithelial cells and tumor
associated stromal areas were investigated separately. The median
follow-up time was 89 months (range 6–188). The last patient
update was November 2012.
Microarray construction
Tissue Microarray (TMA) construction was chosen for high-
throughput molecular pathology analysis [18]. For each case, a
pathologist (ER) histologically identified and marked two cores
with areas of tumor cells (epithelial tumor cells), two cores with
tumor stromal tissue, one core from areas with normal epithelial
cells, and one core with normal stromal tissue. The TMAs were
assembled using a tissue-arraying instrument (Beecher Instru-
ments, Silver Springs, MD, USA). Briefly, we used a 0.6 mm
diameter needle to harvest the marked tissue areas from the
corresponding formalin-fixed paraffin-embedded (FFPE) tissue
blocks. The samples were inserted into an empty recipient paraffin
block according to a coordinate pattern. To include all core
samples, twelve tissue array blocks were constructed. Multiple
4 mm sections were cut with a Micron microtome (HM355S),
affixed to glass slides, and sealed with paraffin. The detailed
methodology has been reported previously [19].
RNA extraction
RNA was isolated from formalin-fixed paraffin-embedded
samples with RecoverAll Total Nucleic Acid Isolation Kit for
FFPE tissue (Life Technologies), and was sent to Exiqon (Vedbaek,
Denmark) which performed the miRNA screening experiment.
Tissue used for RNA extraction was three 4 mm deep, 0.6 mm
diameter cylindrical cores harvested from marked tumor com-
partments from FFPE blocks. The microarray used was LNA
array 6th generation human, rat and viral microarray designed
with a miRNA library with 1435 human, rat and viral miRNA.
Total RNA (500 ng) from both sample and reference was labeled
with Hy3 and Hy5 fluorescent label, respectively, using the
miRCURY LNA microRNA Hi-Power Labeling Kit, Hy3/Hy5
(Exiqon, Denmark) following the procedure described by the
manufacturer. The Hy3-labeled samples and a Hy5-labeled
reference RNA sample were mixed pair-wise and hybridized to
the miRCURY LNA microRNA Array 6th Gen (Exiqon,
Denmark), which contains capture probes targeting all micro-
RNAs for human, mouse or rat registered in the miRBASE 16.0.
The hybridization was performed according to the miRCURY
LNA microRNA Array Instruction manual using a Tecan HS4800
hybridization station (Tecan, Austria). After hybridization, the
microarray slides were scanned and stored in an ozone free
environment (ozone level below 2.0 ppb) in order to prevent
potential bleaching of the fluorescent dyes. The miRCURY LNA
microRNA Array slides were scanned using the Agilent G2565BA
Microarray Scanner System (Agilent Technologies, Inc., USA)
and the image analysis was carried out using the ImaGene 9
(miRCURY LNA microRNA Array Analysis Software, Exiqon,
Denmark). The quantified signals were background corrected and
normalized using the global Lowess (LOcally WEighted Scatter-
plot Smoothing) regression algorithm.
Quantification of mature miRNAs by real-time qPCR
The criteria for selecting miRNAs for PCR validation was;
significant P-value, high fold change and prior plausibility. The
miRNAs chosen for further testing were miR-21, miR-141, miR-
23a, miR-222, miR-205, miR-143 and miR-145 (Table 2). All
real-time qPCR experiments were performed by Exiqon (Ved-
baek, Denmark).
RNA (2 ml) was reverse transcribed in 10 ml reactions using the
miRCURY LNA Universal RT microRNA PCR, Polyadenylation
and cDNA synthesis kit (Exiqon). cDNA was diluted 100 x and
assayed in 10 ml PCR reactions according to the protocol for
miRCURY LNA Universal RT microRNA PCR; each micro-
RNA was assayed in triplicate by qPCR on the microRNA custom
made pick-n-mix panel. Negative controls excluding template
from the reverse transcription reaction was performed and profiled
like the samples. The amplification was performed in a Light-
Cycler 480 Real-Time PCR System (Roche) in 384 well plates.
The amplification curves were analyzed using the Roche LC
software, both for determination of Crossing point (Cp) by the 2nd
derivative method, and for melting curve analysis.
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The amplification efficiency was calculated using algorithms
similar to the LinReg software. All assays were inspected for
distinct melting curves and the melting temperature (Tm) was
checked to be within known specifications for the assay.
Furthermore assays was detected by 5 Cp’s less than the negative
control, and with Cp,37 to be included in the data analysis. Data
that did not pass these criteria were omitted from any further
analysis.
Using NormFinder the best normalizer was found to be the
miR-23b. All data was normalized to this miRNA in all samples
(miR-23b – assay Cp).
In situ hybridization
Chromogen in situ hybridization (cISH) was performed ac-
cording to ‘‘One-day microRNA ISH protocol’’ developed by
Exiqon, Vedbek, Denmark. Labelled locked nucleic acid (LNA)
modified probes from Exiqon for miR-21 (hsa-miR-21miRCURY
LNA Prod. No. 38102-15), positive control (U6 has/mmu/rno)
and negative controls (scramble-miRNA) was used. Some optimi-
zations of the method were done to get a specific and sensitive
detection of miRNA in our sections from FFPE TMAs.
4 mm TMA slides were incubated for three days at 37uC to
attach cores to super Frost Plus slides. Sections were deparaffinised
in xylene (365 min) and then hydrated to ethanol solutions to
PBS, pH 7.4. Proteinase-K 20 mm/ml, treatment was done in PK-
buffer (5 mM Tris-HCL, pH 7.5, 1 mM NaCl, autoclaved) at
37uC for 20 min in a ThermoBrite hybridizer. After PBS wash the
sections were rehydrated through ethanol and air-dried. The
LNA-probes were denatured by heating to 90uC for 4 min.
Hybridization of the LNA-probes miR-21 (50 nM), scrambled
miRNA (50 nM) and U6 (1 nM) were carried out in a
ThermoBrite hybridizer at 50uC for 60 min. Stringent washes
were performed in room temperature 5x SSC buffer, pre-heated
SSC buffers (50uC), 5 min in 5x SSC, 265 min in 1x SSC, 265
min in 0.2 SSC, and 5 min in RT 0.2x SSC. Sections were
blocked against unspecific binding in blocking solution from DIG
wash and Block buffer set (11 585 762 001, Roche, Mannheim,
Germany) for 15 min at RT in a humidity chamber. Alkaline
phosphatase (AP)-conjugated anti DIG (11 093 274 910, Roche,
Mannheim, Germany) 1:800 was incubated for 30 min at RT in a
humidity chamber for immunologic detection. After PBS-T wash
the substrate enzymatic reactions was carried out with NBT/BCIP
(11 697 471 001, Roche, Mannheim, Germany) at 30uC in the
ThermoBrite for 120 min. The reaction was stopped with a 265
min wash in KTBT buffer (50 nM Tris-Hcl, 150 nM NaCl,
10NM KCI) followed by wash in double distilled water. Sections
were counter stained with nuclear fast red (WALDECK, ZE-012-
250) at RT for 1 min and then rinsed in tap water. Dehydration
was accomplished by increasing gradients of ethanol solutions and
finally mounting with Histokitt mounting medium (Assistant-
Histokitt, 1025/250 Sondheim/Rhoen Germany).
Scoring of cISH
The image analysis was performed using the ARIOL imaging
system (Genetix, San Jose, USA) composing of a microscope
(Olympus BX 61) equipped with an automatic stage and slide
loader, together with a camera. The cores were photographed
using 20x magnifications. The dominant staining intensity in
epithelial tumor cells and tumor surrounding stromal cells were
scored as; 0 = negative, 1 = weak, 2 = moderate and 3 = strong. All
samples were anonymized and independently scored by two
pathologists (ER and AV). When assessing one variable for a given
core, the observers were blinded to scores of the other variables
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all four cores and both examiners. In case of disagreement (score
discrepancy .1), the slides were re-examined and consensus was
reached by the observers.
Statistical methods
All Statistical analyses were performed using the statistical
package IBM SPSS, version 21 (SPSS Inc., Chicago, IL, USA)
(S1). Scoring values from each pathologist were compared for
inter-observer reliability by use of a two-way random effect model
with absolute agreement definition. A Wilcoxon signed rank test
was used to assess if it was a statistically significant difference in the
expression of miR-21 between normal tissue and cancer tissue.
When comparing the two sample groups (BF versus non-BF group)
from the qPCR results, two-sided student’s t-test was used. For the
entire cohort, Pearson chi-square tests and Spearman’s Correla-
tion test were performed to examine associations between miR-21
expression and clinicopathological markers. The Kaplan-Meyer
method was used to make plots of BFFS and CFFS. Log-rank test
was used to test for statistical significance. Significant variables
from the univariate analyses were further assessed in the
multivariate survival analysis using a backward stepwise Cox
regression model with a probability for stepwise entry removal at
0.05 and 0.10, respectively. The significance level used was p,
0.05 for all analyses. All survival analyses were carried out using
three different end-points: (i) biochemical failure free survival
(BFFS), (ii) clinical failure free survival (CFFS), and (iii) PC death
free survival (PCDFS). BF was characterized as a PSA$0.4 ng/
mL and rising in a minimum of two different blood samples
postoperatively. CF was defined as verified local symptomatic
progression and/or verified metastasis to bone, visceral organs or
lymph nodes on CT, MR, bone scan or ultrasonography. PCDFC
was defined as death caused by progressive PC.
Results
Patients’ characteristics and clinicopathological variables
Total cohort. An overview of the patient cohort’s demo-
graphic, clinical and histopathological characteristics is presented
in Table 1. Median age at surgery was 62 (range 45–75). The
prostatectomies were retropubic in 435 cases and perineal in 100
cases. At last follow-up, 170 patients had experienced BF, 36 CF,
and 15 patients were dead of PC.
miRNA screening subgroup. In the 30 patients with
Gleason score 7 who underwent miRNA screening, median age
was 65 years (range 57–71), median PSA 18.8 ng/mL (range 5–
79), median tumor size 22 mm (range 3–45), 21% experienced CF
and 14% were dead of prostate cancer. In the total group of
patients with Gleason score 7 (n = 270), median age was 62 (range
47–74), median PSA 18.0 ng/mL (range 0.7–71), median tumor
size 23 mm, 22% experienced CF and 9% were dead of prostate
cancer. None of these differences were statistically significant.
Microarray screening and qPCR validation
600 of 1435 miRNAs investigated by microarrays, had expres-
sion above background (background signal strength defined as 1.2
times the intensity of the 1-quartile each slide) (Table 2). Of these,
50 miRNAs with the highest standard deviation (SD) were further
analyzed. From the microarray analyses, a hierarchical 2D-
clustering showed a relative expression level of miRNAs that were
up-regulated in both groups (Figure 1a). Expression levels of
7 miRNAs were validated by RT-qPCR (Table 3, Figure 1a). Five
of seven analyzed miRNAs showed similar trend in the two
groups. The Heat Map diagram shows the result of the two-way
hierarchical clustering of the expression level of the five miRNAs.
The z-score was cropped from 22 to +2 (Figure 1b). miR-21 was
the only miRNA that was significantly up-regulated in the BF
group. This was in concordance with the array results. There was
a strong correlation between the array hybridization and qRT-
PCR.
Expression of miR-21 and correlations in the total cohort
In general, miR-21 was expressed at a higher level in tumor
stromal areas than in tumor epithelial cells (Figure 2). The
intensity of miR-21 expression was stronger in cytoplasm of tumor
tissue compared to normal tissues from the patients (p,0.001).
There was no difference in miR-21 expression between tumor
epithelial cells and normal epithelial cells. A significant higher
expression of miR-21 was found in tumor stromal area than in
non-neoplastic stromal area (p,0.001). By comparing tumor
epithelial cells with tumor stromal cells, miR-21 was expressed at
higher levels in tumor stromal cells (p,0.001).
There were significant correlations between high tumor stromal
expression of miR-21 and pT-stage (r = 0.134, p = 0.003),
perineural infiltration (PNI) (r = 0.175, p,0.001) and vascular
infiltration (r = 0.222 p,0.001). We found a weak correlation
between stromal expression of mir-21 and Gleason score
(r = 0.218, p,0.001). There were also significant correlations
between stromal expression of miR-21 and Gleason Score (GS);
GS ,7, GS 7 and GS.7 (r = 0.238, p,0.001).
Table 3. The most up- or down-regulated miRNAs in rapid BF group versus non-BF group.
Microarray RT-qPCR
miR Fold change p Fold change p
Up-regulated hsa-miR-141* 0.42 0.32 1.09 0.08
hsa-miR-143 –0.42 0.34 0.10 0.74
hsa-miR-21 0.31 0.46 0.89 0.05
hsa-miR-23a –0.28 0.38 0.12 0.34
Down-regulated hsa-miR-145 –0.62 0.31 –0.15 0.58
hsa-miR-205 –0.70 0.31 –0.48 0.68
hsa-miR-222 –0.33 0.30 –0.22 0.35
Two-sided Student’s t-test: miR-21 was significant (cut-off: p-value,0.5).
*One-sided Student’s t-test: miR-141 was significant. Abbreviations: BF; biochemical failure.
doi:10.1371/journal.pone.0113039.t003
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Figure 1. Linkage hierarchical unsupervised clustering of differentially expressed miRNAs. a) Relative expression levels of 50 miRNAs
that were expressed in all 30 matched tissue samples with Gleason score 7. The X-axis shows individuals and the Y-axis shows miRNAs. Red squares
encode for up-regulated miRNAs and green squares encode for down-regulated miRNAs. b) Heat Map results of the two-way hierarchical clustering
Stromal MiR-21 Predicts Biochemical Failure in Prostate Cancer
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There were no differences in stromal expression of miR-21
between the subgroups of Gleason score, 3+4 (n = 220, 41%) and
4+3 (n = 80, 15%) (r = – 0.001, p = 0.991).
Univariate analysis
The clinicopathological variables pT-stage (p,0.001), preoper-
ative PSA value dichotomized at 10 ng/dL (n = 221, p,0.001),
Gleason score (p,0.001), tumor size dichotomized at 20 mm
(n = 285, p,0.001), perineural infiltration (PNI) (no = 134, p,
0.001), positive surgical margins (PSM) (n = 286, p = 0.041),
positive surgical circumferential margin (n = 154, p,0.001),
positive surgical apical margin (n = 210, p = 0.04), and vascular
infiltration (n = 43, p,0.001) were all significantly correlated to
BFFS in the univariate survival analyses (Table 1).
The 4th quartile was used as cut-off. A high expression of miR-
21 in tumor stromal areas was significantly correlated with BF
(n = 170, p = 0.006, Figure 3a), and CF (n = 36, p = 0.041, figure
not shown.) There was no correlation between high stromal
expression of miR-21 and PCD (n = 14, p = 0.505).
based on the qPCR results. The miRNAs showed the same trend in qPCR validation and in the microarray analysis. The normalized (dCp) values have
been used for the analysis. Red color represents an expression level above mean, blue color represents expression lower than the mean.
doi:10.1371/journal.pone.0113039.g001
Figure 2. In situ hybridization (ISH) analysis of prostate cancer representing Gleason Grade (GS) ,7 (A), GS 7 (B) and GS,7 (C),
(200x and 400x magnification).
doi:10.1371/journal.pone.0113039.g002
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In subgroup analyses we found high stromal expression of miR-
21 to be significantly associated with increased risk for BF in
patients with GS 6 (n = 167, p = 0.023, Figure S3b), but this were
not found for patients with GS 7 (n = 262, p = 0.228), Gleason
grade 3+4 (n = 189, p = 0.0290, Gleason grade 4+3 (n = 73,
p = 0.818), and GS .7 (n = 36, p = 0.895). We also found high
stromal expression correlated to BF for the patients with positive
circumferential margins (n = 139, p = 0.026), but not for those with
free circumferential margins (n = 339, p = 0.107).
Multivariate analysis
Significant clinicopathological and molecular markers from
univariate analysis were entered into the multivariate model.
Table 4 presents the independent prognostic factors for BF; pT-
stage (p = 0.001), Gleason grade (p = 0.021), non-apical PSM
(n = 286, p = 0.001), apical PSM (n = 210, p = 0.003). For CF;
Gleason grade (p = 0.013), PNI (n = 134, p = 0.028), non-apical
PSM (p = 0.028).
High stromal expression of miR-21 was an independent
prognostic factor for BF in patients with Gleason score 6
(n = 167, HR 2.40, CI 95% 1.06–5.49, p = 0.037). A significant
association between high stromal expression of miR-21 and BF
was also found in the subgroup of patients with PSM (HR 1.95, CI
95% 1.95–3.21, p = 0.008). However, for the entire cohort
(n = 471), there was only a trend towards an independent
association between stromal expression of miR-21 and BF
(n = 170, p = 0.089). High stromal expression of miR-21 was not
an independent prognostic variable for CF (n = 36, p = 0.395).
Discussion
In this study, we found a higher expression of miR-21 in cancer
tissues compared with normal prostatic tissue. The expression was
highest in tumor stromal areas. High tumor stromal expression of
miR-21 was an independent prognostic factor for biochemical
failure in patients with Gleason grade 6 but not clinical failure,
probably due to few events in the latter group. To our knowledge,
this is the first study reporting tumor stromal expression of miR-21
as a prognostic marker for BF after radical prostatectomy.
Moreover, we also found a high stromal expression to be an
independent marker for PSM in RP specimens.
Recent studies have shown that miRNAs are significantly
altered in prostate cancer, suggesting that miRNAs act as key
regulators of prostate carcinogenesis. Several studies have been
conducted to identify the PC-specific miRNA signature, but n
consensus has been reached with respect to miRNAs role in
development and progression of PC [20,21]. In a study by Violinia
et al. [22], total RNA was extracted from 363 solid cancers,
including prostate cancer, and 177 normal tissues. They found a
general up-regulation of 39 miRNAs, including miR-21, whereas
6 miRNAs were down-regulated. These results were in partial
agreement with a study by Ambs et al. in which total RNA
extracted from 60 micro-dissected PC and 16 surrounding non-
tumor tissues were analyzed [23]. MiR-21 is generally considered
an oncogene, but so far its role in PC is unclear and the reports
have been conflicting [11,12,14,20]. miR-21 has been found to be
elevated in PC3 and DU145 androgen-independent cell lines [24].
Moreover, miR-21 was identified as an androgen receptor-
regulated miRNA whose level was elevated in PC compared with
adjacent normal tissue [12]. Inhibitions of miR-21 diminish
androgen-induced PC cell proliferation, whereas elevated expres-
sion of miR-21 promotes enhanced tumor growth and castration
resistance in vivo [12]. Others have also found miR-21 up-
regulated in patients with hormone- and chemoresistant PC
[13,15].
We found that a high tumor stromal expression of miR-21 in
tumors with Gleason score 6 predicted BF. This is in line with
previous reports [25]. Stromal miR-21 expression analysis may be
a potential tool to predict which highly differentiated tumors that
is most likely to progress. Recent studies have provided valuable
insights in clarifying the involment of miR-21 in tumor microen-
vironment: Bullock et al. [26] demonstrated that upregulated miR-
21 expression occurs in cancer-associated stromal cells but not in
colo-rectal cancer cells. Moreover, they found that ectopic miR-21
expression in fibroblasts modulated the cytotoxic impact of
Oxaliplatin (chemotherapheutic used in treatment of colon cancer)
which resulted in cancer progression. Bronisz et al. [27]
demonstrated that downregulation of mir-320 in mammary
stromal fibroblasts reprograms the tumor microenvironment by
activating a pro-oncogenic secretome, and interestingly, Yao et al.
[28] reported that myofibroblast transdifferentiation from progen-
itor fibroblasts in response to TGF-b could be prevented using
specific antisense inhibitors of miR-21. Together, these data
suggest pro-metastatic influence of mRNAs in fibroblast differen-
tiation and phenotype, and that miR-21 may be mediated through
the tumor microenvironment. However, biological and functional
Figure 3. Disease-specific survival according to biochemical
failure and high stromal expression of miR-21 in: a) Total
cohort. b) Patients with Gleason score 6.
doi:10.1371/journal.pone.0113039.g003
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evidence to support these findings, especially prostate carcinomas,
is limited.
It is well known that less than 3% of patients with Gleason
score#6 will ever progress whether treated or not, and that a
substantial percentage of these patients continue to undergo
unnecessary treatment following a diagnosis of low risk PC (based
on a PSA,10 ng/mL and stage # T2a) [29,30]. Stromal miR-21
expression analysis may be a potential tool to predict which highly
differentiated tumors that is most likely to progress. Further studies
to clarify the exact role of miR-21 in these highly differentiated
tumors are needed. In contrast to previous reports, we found high
expression of miR-21 in patients with positive surgical margins,
[25]. The molecular mechanisms for this are unknown.
The divergent results of miR-21 in different studies might reflect
the heterogeneity of PC, as well as different study design and
methodology. A miRNA screening of the entire cohort would have
strengthened our study. Besides, quality of the tissues examined
(including handling) can drastically affect the interpretation of
microarray data. Besides the interesting data on BF, our study is
somewhat limited by the low number of cases with clinical relapse
or PCD. Further studies of this microRNA and its associated
pathways may uncover new mechanisms for cancer progression
and therapeutic intervention.
Conclusion
This study on miRNA profiling and validation in prostate
cancer adds further evidence for miR-21 as a prognostic marker
for PC. These results indicate that stromal expression of miR-21
has an important role in disease progression, but the underlying





We thank the participating laboratory technicians at the Department of
Pathology, UNN for their support and technical skills. Especially we wish
to thank Magnus Persson, Mona Pedersen and Marit Nina Nilsen,
Christopher Fenton, Øystein Størkersen and Anders Angelsen.
Author Contributions
Conceived and designed the experiments: CMJ SA YK LTB AV RMB TB
ER. Performed the experiments: CMJ SA TD YK TB ER. Analyzed the
data: CMJ SA TD LTB RMB ER. Contributed reagents/materials/
analysis tools: CMJ NN SA AV TD SAS LTB RMB YK YN ER.
Contributed to the writing of the manuscript: CMJ SA AV SAS YK TD
LTB RMB ER.
References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer
statistics. CA Cancer J Clin 61(2): 69–90
2. Etzioni R, Mucci LA, Chen S, Johansson JE, Fall K, et al. (2012) Increasing use
of radical prostatectomy for non-lethal prostate cancer in Sweden. Clin Cancer
Res 15; 18(24): 6742–6747.
3. Breidablikk HJ, Meland E, Aakre KM, Forde OH (2013) PSA measurement and
prostate cancer – overdiagnosis and overtreatment? Tidsskr Nor Laegeforen
16(3): 1711–1716.
4. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function.
Cell 116(2): 281–297.
5. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell
136(2): 215–233.
6. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, et al. (2004) Human
microRNA genes are frequently located at fragile sites and genomic regions
involved in cancers. Proceedings of t Proc Natl Acad Sci U S A 2; 101(9):
2999–3004.
7. Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, et al. (2006) Optimized
high-throughput microRNA expression profiling provides novel biomarker
assessment of clinical prostate and breast cancer biopsies. Molecular Cancer 5:
24.
8. Prueitt RL, Yi M, Hudson RS, Wallace TA, Howe TM, et al. (2008) Expression
of microRNAs and protein-coding genes associated with perineural invasion in
prostate cancer. The Prostate 68(11): 1152–1164.
9. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, et al. (2007)
MicroRNA expression profiling in prostate cancer. Cancer Res 67(13): 6130–
6135.
10. Chan JA, Krichevsky AM, Kosik KS (2005) MicroRNA-21 is an antiapoptotic
factor in human glioblastoma cells. Cancer Res 65(14): 6029–33.
Table 4. Results of Cox regression analysis of significant independent clinicopathological actors and high tumour stromal
expression of mir-21 versus BF and CF.
Biochemical Failure (BF) Clinical Failure (CF)
Variable HR (95% CI) p HR (95% CI) p
pT-Stage pT2 1 ,0.001 Not Significant
pT3a 1.7 (1.1–2.5) 0.011
pT3b 2.6 (1.6–4.2) ,0.001
Preop PSA 1.4 (1.0–1.9) 0.069 Not Significant
Gleason 3+3 1 0.021 1 0.013
3+4 1.0 (0.7–1.5) 0.999 2.7 (0.9–8.6) 0.085
4+3 1.5 (0.9–2.4) 0.125 3.5 (1.0–12.1) 0.047
8–10 1.9 (1.3–2.7) 0.008 6.6 (2.1–21.2) 0.002
Perineural infiltration Not Significant 2.3 (1.1–4.7) 0.031
Vascular infiltration Not Significant Not Significant
Apical PSM 0.6 (0.4–0.8) 0.003 Not Significant
Non-apical PSM 1.9 (1.3–2.7) ,0.001 2.9 (1.4–6.1) 0.004
hsa-miR-21 1.4 (1.0–1.9) 0.089 Not Significant
doi:10.1371/journal.pone.0113039.t004
Stromal MiR-21 Predicts Biochemical Failure in Prostate Cancer
PLOS ONE | www.plosone.org 10 November 2014 | Volume 9 | Issue 11 | e113039
11. Hulf T, Sibbritt T, Wiklund ED, Bert S, Strbenac D, et al. (2011) Discovery
pipeline for epigenetically deregulated miRNAs in cancer: integration of primary
miRNA transcription. BMC genomics 21; 12: 54.
12. Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, et al. (2009) miR-21: an
androgen receptor-regulated microRNA that promotes hormone-dependent and
hormone-independent prostate cancer growth. Cancer Res 69(18): 7165–7169.
13. Ribas J, Lupold SE (2010) The transcriptional regulation of miR-21, its multiple
transcripts, and their implication in prostate cancer. Cell Cycle 9(5): 923–929.
14. Folini M, Gandellini P, Longoni N, Profumo V, Callari M, et al. (2010) miR-21:
an oncomir on strike in prostate cancer. Mol Cancer 21; 9: 12.
15. Shi GH, Ye DW, Yao XD, Zhang SL, Dai B, et al. (2010) Involvement of
microRNA-21 in mediating chemo-resistance to docetaxel in androgen-
independent prostate cancer PC3 cells. Acta Pharmacol Sin 31(7): 867–873.
16. Epstein JI, Allsbrook WC Jr., Amin MB, Egevad L, Committee IG (2005) The
2005 International Society of Urological Pathology (ISUP) Consensus
Conference on Gleason Grading of Prostatic Carcinoma. American J Surg
Pathol 29(9): 1228–1242.
17. Cheng L, Montironi R, Bostwick DG, Lopez-Beltran A, Berney DM (2012)
Staging of prostate cancer. Histopathol 60(1): 87–117.
18. Kielhorn E, Provost E, Olsen D, D’Aquila TG, Smith BL, et al. (2003) Tissue
microarray-based analysis shows phospho-beta-catenin expression in malignant
melanoma is associated with poor outcome. Int J Cancer 20; 103(5): 652–656.
19. Bremnes RM, Veve R, Gabrielson E, Hirsch FR, Baron A, et al. (2002) High-
throughput tissue microarray analysis used to evaluate biology and prognostic
significance of the E-cadherin pathway in non-small-cell lung cancer. J Clin
Oncol 20(10): 2417–2428.
20. Coppola V, De Maria R, Bonci D (2010) MicroRNAs and prostate cancer.
Endocr Relat Cancer 29; 17(1): F1–17.
21. Gandellini P, Folini M, Zaffaroni N (2009) Towards the definition of prostate
cancer-related microRNAs: where are we now? Trends Mol Med 15(9): 381–
390.
22. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, et al. (2006) A microRNA
expression signature of human solid tumours defines cancer gene targets. Proc
Natl Acad Sci U S A 14; 103(7): 2257–2261.
23. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, et al. (2008) Genomic
profiling of microRNA and messenger RNA reveals deregulated microRNA
expression in prostate cancer. Cancer Res 68(15): 6162–6170.
24. Li T, Li D, Sha J, Sun P, Huang Y (2009) MicroRNA-21 directly targets
MARCKS and promotes apoptosis resistance and invasion in prostate cancer
cells. Biochem Biophys Res Commun 5; 383(3): 280–285.
25. Li T, Li RS, Li YH, Zhong S, Chen YY, et al. (2012) miR-21 as an independent
biochemical recurrence predictor and potential therapeutic target for prostate
cancer. J Urol 187(4): 1466–1472.
26. Bullock MD, Pickard KM, Nielsen BS, Sayan AE, Jenei V, et al. (2013)
Pleiotropic actions of miR-21 highlight the critical role of deregulated stromal
microRNAs during colorectal cancer progression. Cell Death Dis 4: e684.
27. Bronisz A, Godlewski J, Wallace JA, Merchant AS, Nowicki MO, et al. (2012)
Reprogramming of the tumour microenvironment by stromal PTEN-regulated
miR-320. Nat Cell Biol 14: 159–167.
28. Yao Q, Cao S, Li C, Mengesha A, Kong B, et al. (2011) Micro-RNA-21
regulates TGF-beta-induced myofibroblast differentiation by targeting PDCD4
in tumor-stroma interaction. Int J Cancer 128: 1783–1792.
29. Mohler JL (2010) NCCN clinical practice guidelines in oncology on prostate
cancer. Journal of the National Comprehensive Cancer Network: JNCCN 8(2):
145.
30. Arora R, Koch MO, Eble JN, Ulbright TM, Li L, et al. (2004) Heterogeneity of
Gleason grade in multifocal adenocarcinoma of the prostate. Cancer 100(11):
2362–2366.
Stromal MiR-21 Predicts Biochemical Failure in Prostate Cancer
PLOS ONE | www.plosone.org 11 November 2014 | Volume 9 | Issue 11 | e113039
